In This Article:
Champions Oncology (NASDAQ:CSBR) Third Quarter 2025 Results
Key Financial Results
-
Revenue: US$17.0m (up 42% from 3Q 2024).
-
Net income: US$4.50m (up from US$2.53m loss in 3Q 2024).
-
Profit margin: 26% (up from net loss in 3Q 2024). The move to profitability was primarily driven by higher revenue.
-
EPS: US$0.33 (up from US$0.19 loss in 3Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Champions Oncology Earnings Insights
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 8.2% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Champions Oncology that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.